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CCNE1 amplification is associated with
poor prognosis in patients with triple
negative breast cancer
Zi-Ming Zhao1, Susan E. Yost2, Katherine E. Hutchinson3, Sierra Min Li2, Yate-Ching Yuan2, Javad Noorbakhsh1,
Zheng Liu2, Charles Warden2, Radia M. Johnson3, Xiwei Wu2, Jeffrey H. Chuang1† and Yuan Yuan2*†

Abstract
Background: Triple negative breast cancer (TNBC) is aggressive with limited treatment options upon recurrence.
Molecular discordance between primary and metastatic TNBC has been observed, but the degree of biological
heterogeneity has not been fully explored. Furthermore, genomic evolution through treatment is poorly
understood. In this study, we aim to characterize the genomic changes between paired primary and metastatic
TNBCs through transcriptomic and genomic profiling, and to identify genomic alterations which may contribute
to chemotherapy resistance.
Methods: Genomic alterations and mRNA expression of 10 paired primary and metastatic TNBCs were
determined through targeted sequencing, microarray analysis, and RNA sequencing. Commonly mutated
genes, as well as differentially expressed and co-expressed genes were identified. We further explored the
clinical relevance of differentially expressed genes between primary and metastatic tumors to patient survival
using large public datasets.
Results: Through gene expression profiling, we observed a shift in TNBC subtype classifications between
primary and metastatic TNBCs. A panel of eight cancer driver genes (CCNE1, TPX2, ELF3, FANCL, JAK2, GSK3B,
CEP76, and SYK) were differentially expressed in recurrent TNBCs, and were also overexpressed in TCGA and
METABRIC. CCNE1 and TPX2 were co-overexpressed in TNBCs. DNA mutation profiling showed that multiple mutations
occurred in genes comprising a number of potentially targetable pathways including PI3K/AKT/mTOR, RAS/MAPK, cell
cycle, and growth factor receptor signaling, reaffirming the wide heterogeneity of mechanisms driving TNBC. CCNE1
amplification was associated with poor overall survival in patients with metastatic TNBC.
Conclusions: CCNE1 amplification may confer resistance to chemotherapy and is associated with poor overall survival
in TNBC.
Keywords: Triple negative breast cancer, CCNE1, Amplification

Background
Triple negative breast cancer (TNBC) is an aggressive
type of breast cancer (BC) characterized by a high rate
of recurrence and poor overall survival upon cancer metastasis [1, 2]. Hormone-receptor positive (HR+) BCs
and HER2-positive (HER2+) BCs harbor well-defined
* Correspondence: yuyuan@coh.org
†
Jeffrey H. Chuang and Yuan Yuan contributed equally to this work.
2
City of Hope Comprehensive Cancer Center and Beckman Research
Institute, 1500 E. Duarte Road, Duarte, CA 91010, USA
Full list of author information is available at the end of the article

and targetable biomarkers. Despite the identification of
at least four molecular TNBC subtypes, including basallike 1 (BL1), basal-like 2 (BL2), mesenchymal (M), and
luminal androgen receptor (LAR) [3–5], these subtypes
have not proven clinically useful due to the intrinsically
complex and heterogeneous biology of TNBCs. With the
exception of PARP inhibitors for patients with BRCA1/2
germline mutations, and unlike HR+ or HER2+ BCs,
there is no effective targeted therapy available to treat
TNBCs.
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In addition to tumor heterogeneity, the biology of
TNBC is further complicated by tumor evolution through
selective pressure. The molecular evolution of TNBC as
the result of chemotherapy and/or radiation-induced selection pressure is well recognized but poorly understood
[6]. Molecular discordance between primary and metastatic TNBCs has been observed, but the degree of biological heterogeneity has not been fully explored [7].
Recurrent/resistant BC may differ from primary tumors at multiple levels. Several previous studies demonstrated phenotypic discordances between primary and
metastatic tumors in the standard-of-care biomarkers estrogen receptor (ER), progesterone receptor (PR), and
HER2 [8, 9]. Discordance of other molecular markers
such as PIK3CA mutations was also identified [9, 10].
Cyclin E1 (CCNE1), along with its catalytic subunit
CDK2, plays a critical role in cell cycle regulation, DNA
replication, chromosome segregation, and the G1 to
S-phase transition [11, 12]. CCNE1 amplification is associated with primary treatment resistance in high-grade serous ovarian carcinomas (HGSCs) and co-amplification of
TPX2 with CCNE1 was common [13, 14]. CCNE1 amplification is also associated with resistance to HER2-targeted
therapy in HER2+ BC [15]. However, the role of CCNE1
in TNBC is not well understood.
Genomic and transcriptomic discordance between primary and metastatic tumors have the potential to reveal
novel drivers of metastatic progression, and aid in the
selection of late-line therapies [16]. Genomic sequencing
has revealed subclonal diversity of primary BCs and
chemotherapy-resistant BCs in experimental models
[17], but such findings have not been shown in patient
tumor samples. Available large-scale public genomic databases from The Cancer Genome Atlas (TCGA) project
[18] and the Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC) [19] have significantly improved our understanding of breast cancer
tumor biology. These data sets contain only newly diagnosed and chemotherapy naïve tumors as opposed to
complementary longitudinal primary and metastatic
samples. Therefore, genomic characterization of longitudinal samples has the potential to identify novel driver
mutations and therapeutic targets.
The primary goal of this study is to characterize the
genomic changes between paired primary and metastatic
TNBCs through sequencing and mRNA expression profiling, and to identify genomic alterations which may
contribute to chemotherapy resistance.

Methods
Cohort of paired primary and recurrent/metastatic TNBC
specimens

Paired primary and recurrent TNBC specimens were identified through an IRB-approved protocol from patients with
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recurrence between 2002 and 2015. Eligible patients had
the following features: stage I - III TNBC; at least one
tumor biospecimen available from initial surgery or biopsy;
at least one specimen available from a recurrent/metastatic
disease; and treatment and clinical outcome data available
for chart review. Two cohorts of patients were studied:
“Pilot-TNBC” (n = 10) and “Discovery-TNBC” (n = 55).
All pathology samples were formalin-fixed and paraffinembedded (FFPE). Demographic data such as age, gender, date of birth, date of diagnosis, date of relapse, and
date of death or last follow-up (if applicable) were obtained for CCNE1 amplified patients (n = 13, 6 from
“Discovery-TNBC”, and 7 from clinical report). Disease
characteristics such as tumor grade, TNM stage, and
ER/PR/HER2 status, as well as treatment variables including surgery, chemotherapy, and radiation therapy
were also obtained.
Gene expression profiling of paired TNBCs

Paired primary and recurrent TNBC samples were profiled using the Affymetrix Human GeneChip® 2.0 in the
“Pilot-TNBC” cohort. Robust multi-array averages (RMA
[20]) were calculated from mRNA expression, summarized at the gene symbol level (23,945 gene symbols)
based upon probe-set annotations (instead of transcript
clusters) with the Affymetrix Power Tools software [21].
Messenger RNA (mRNA) expression across control
probe transcript clusters was also summarized (27,293
control probes). Gene symbol annotations for probe sets
were downloaded from the Affymetrix website. When
comparing expression between primary and recurrent
samples, p-values were calculated using the limma R
package [22] and false discovery rate (FDR) values were
calculated using the method of Benjamini and Hochberg
[23]. The number of differentially expressed genes was
maximized by considering genes with RMA > 2 in at
least 50% of samples, |fold-change| > 1.5 between averaged recurrent and primary tumors, and FDR < 0.25.
The ratio of gene expression between paired recurrent
and primary TNBCs was reported as fold-change. Heat
maps and clustering of differentially expressed genes
were created using the ‘seaborn’ package under Jupyter
Notebook Python 3. For better visualization, we only reported fold changes between − 10 and 10. TNBC subtyping was performed using the online TNBC Type tool
from Vanderbilt University Medical Center [24]. Of the
“Discovery-TNBC” cohort (n = 55), RNA isolation and
expression profiling were performed for 35 paired
primary-metastatic specimens. Total RNA was isolated
from FFPE specimens using the QIAGEN miRNeasy
FFPE kit. RNA integrity (RIN) and DV200 scores were
determined using an Agilent Bioanalyzer. Per Illumina
protocol, TruSeq RNA Access Library Preparation was
performed, and libraries were enriched for mRNA
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fraction by positive selection, prior to paired-end 2 × 100
sequencing on the Illumina HiSeq. Using the R package
“edgeR version 3.20.9” [25, 26], raw transcript counts
were converted to log2-counts per million (log2CPM),
dataset-wide lowly- or non-expressed genes were removed,
and transcript expression was normalized to ensure similar
expression distributions across the dataset.
Targeted exome sequencing of TNBCs

Genomic alterations in FFPE specimens from primary
and recurrent TNBCs were detected using the FoundationOne™ sequencing panel. FoundationOne™ identifies
base substitutions, insertions and deletions (indels), amplifications with copy number ≥ 6, and rearrangements.
The FoundationOne™ sequencing panel version used
herein included the entire coding regions of 395 cancerrelated genes, and select introns of 31 genes that are rearranged or altered in cancer, capable of achieving a median
sequencing depth greater than 500X [27, 28].
Comparison of gene expression using public databases

Gene expression of 1904 samples from METABRIC (299
TNBC and 1605 non-TNBC) using Illumina HT-12 arrays were downloaded [19]. Whole-transcriptome sequences of 1091 primary breast cancer (115 TNBC and
976 non-TNBC) and 112 normal cases in TCGA were
downloaded in the format of ‘illuminahiseq_rnaseqv2-RSEM_genes_normalized (MD5)’ from FireBrowse [18].
Boxplots for gene expression comparisons in METABRIC
[19] and TCGA [18] datasets were created using the R
“ggplot” package. TCGA data were transformed to log2 of
the gene expression value plus 1, to make them the same
scale as the METABRIC gene expression data. P-values
were independently calculated using Wilcoxon and

ANOVA tests to compare between two, and among multiple groups, respectively.
Statistical analysis

Kaplan-Meier (K-M) curves were generated for overall
survival (OS) and relapse free survival (RFS), where OS
is defined as time from surgery to death, and RFS is defined as time from surgery to disease recurrence. The
log-rank test was used to examine survival (OS or RFS)
difference based on CCNE1 copy number alteration
(CN ≥ 6 vs. CN < 6), or CCNE1 mRNA expression (median gene expression as a bifurcation).

Results
Patient characteristics and treatment history

The clinical characteristics, pathological features, treatment histories, and survival of the “Pilot-TNBC” cohort
are described in Table 1. The majority of the tumors were
infiltrating ductal carcinomas (IDC) (80%, 8/10), stage I-II
(70%, 7/10), and the patients received standard-of-care
chemotherapy with anthracycline and/or a taxane-containing regimen. RFS ranged from 2 to 39 months, and
overall survival ranged from 9 to 113 months. Molecular
subtypes according to the Lehmann/Pietenpol classification were determined: BL-1 (n = 4), BL-2 (n = 1), M
(n = 3), and LAR (n = 2). Four of ten TNBC pairs displayed a shift in the molecular subtype between the
primary and metastatic specimens.
Genomic and transcriptomic profiling of paired TNBCs in
the “Pilot-TNBC” cohort

In “Pilot-TNBC,” FoundationOne™ sequencing was
successful in 7 paired specimens (n = 14) (Fig. 1a). A
total of 339 genomic alterations including 73 known

Table 1 Patient characteristics in the “Pilot-TNBC” cohort
Pt ID

Spec# 1

Spec# 2

Histology

Age range

Stage

Lehmann
subtypes

(Neo)adjuvant
chemo

Radiation

RFS (months)

OS (months)

1

Breast

Lung Met

IDC

60–69

II

BL2 → BL2

AC-T

Yes

34

113

2

Breast

Bone Met

IDC

50–59

II

LAR→LAR

AC

No

17

60

3

Breast

LN Met

IDC

40–49

II

BL1 → BL1

AC

No

39

92

4

LN

Liver Met

IDC

40–49

III

BL1 → LAR

Carbo/Taxol

Yes

10

20

5

Breast

Skin Met

IDC

30–39

III

M→M

AC

Unknown

2

9

6

Brain

Soft tissue
Met

IDC

50–59

II

M→M

TAC

No

31

67

7

Breast

LN Met

IDC

50–59

I

BL1 → BL2

Declined

No

26

46

8

Endometrium

LN Met

IDC

30–39

III

M → LAR

TC

Unknown

11

58

9

Breast

Contralateral
breast Met

ILC

40–49

II

LAR→BL2

AC-T

Yes

8

23

10

Breast

Brain Met

Metaplastic

50–59

II

BL1 → BL1

AC-T

Unknown

16

58

IDC invasive ductal carcinoma, LN lymph node, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death), ILC invasive lobular
carcinoma, AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide - > paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/
cyclophosphamide, TC docetaxel /cyclophosphamide, Met metastatic tumor, BL1 basal-like 1, BL2 basal-like 2, M mesenchymal, LAR luminal androgen receptor,
Spec specimen
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Fig. 1 Genomic profiling of the “Pilot-TNBC” cohort. a Tile plot illustrating patients (columns) ordered by primary/metastatic status and by mutation
frequency for the top 25 mutated genes; b Stacked bar plot illustrates the frequency of mutations observed in specific cellular signaling pathways: cell
cycling, p53, PI3K/mTOR, RAS/MAPK, and RTK/GF signaling pathways [29]. Variants of unknown significance (VUS) were included for these analyses. Wt,
wild type; SubIns, substitution and insertion; Sub, substitution; Ins, insertion; Del, deletion, Met, metastatic tumor; Prim, primary tumor

mutation/amplification and 266 variants of unknown significance (VUS) were identified. Genomic alterations were
identified in the following signaling pathways: cell cycle,
p53, PI3K/mTOR, RAS/MAPK, and RTK/GF (Fig. 1b)
[29]. There were no CCNE1 mutations or amplifications
detected in the “Pilot-TNBC” cohort. Detailed genomic alteration data is listed in Additional file 1: Table S3. In
addition, there was significant inter-patient genomic heterogeneity but little intra-patient variability. These findings not only confirm the genomic heterogeneity of
TNBCs, but also highlight the genomic stability of these
tumors over the course of time.
To identify genes driving cancer recurrence, gene expression patterns were studied by comparing the paired
TNBCs in “Pilot-TNBC.” We found 455 differentially
expressed genes (DEG) between metastatic/primary
TNBCs (> 1.5 fold changes), with 317 genes upregulated
and 138 genes down-regulated in the metastatic TNBCs
compared to their matched primaries (Fig. 2a). From the
455 DEGs, the expression of 8 cancer-related genes
(CCNE1, TPX2, GSK3B, CEP76, SYK, JAK2, ELF3 and
FANCL) was significantly upregulated in recurrent/
metastatic TNBCs compared with matched primaries
(Fig. 2b). These genes represent potential cancer driver
genes, selected based on putative cancer driver gene
lists from literature [27, 30–34] and/or inclusion in

the FoundationOne™ targeted sequencing panel. There
was no clear association between expression pattern of
these genes and Lehmann/Pietenpol subtypes of TNBC
(data not shown).
CCNE1 and TPX2 mRNA expression in primary breast cancer

We next analyzed whether genes upregulated in TNBC
metastases had systematic expression patterns across
breast cancer datasets. To further understand genomic
and transcriptomic expression of CCNE1 and TPX2 in
primary TNBCs, public databases including METABRIC
and TCGA were used. TNBCs exhibited higher mRNA
expression of both genes compared with non-TNBCs. In
METABRIC, the percentage of tumors with CCNE1
mRNA overexpression (above median) is significantly increased in TNBCs (42.1%, 126/299) compared with
non-TNBCs (3.2%, 51/1605) (p < 0.0001). In TCGA,
similar results were found in TNBCs (48.7%, 56/115)
compared with non-TNBCs (7.2%, 70/976) (p < 0.0001).
In METABRIC, TNBCs also exhibited higher TPX2
mRNA overexpression (22.4%, 67/299) compared with
non-TNBC (2.4%, 38/1605) (p < 0.001). In TCGA, similar
results were found for TPX2 mRNA overexpression in
TNBCs (40.9%, 47/115) compared with non-TNBCs
(7.6%, 74/976) (p < 0.0001) (Fig. 3a and b). In addition,
CCNE1 and TPX2 are co-overexpressed in TNBC
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Fig. 2 Differential mRNA gene expression analysis between matched primary and metastatic tumors in “Pilot-TNBC” patients (n = 8). a Heatmap
illustrating mRNA expression fold changes (metastatic versus primary, > 1.5) of 455 differentially expressed genes. Three hundred seventeen genes
were upregulated and 138 genes were downregulated in metastatic disease versus primary disease. b Heatmap highlighting the eight putative
cancer driver genes that were upregulated in metastatic TNBCs: CCNE1, TPX2, GSK3B, CEP76, SYK, JAK2, ELF3 and FANCL

(METABRIC, n = 299, p ≤ 0.001; TCGA, n = 115, p ≤ 0.001)
(Fig. 3c and d). Furthermore, CCNE1 is significantly cooverexpressed with TPX2 in “Pilot-TNBC” and “DiscoveryTNBC” cohorts (p < 0.001) (Additional file 2: Figure S2).
However, CCNE1 or TPX mRNA overexpression in TNBCs
did not confer a difference in OS (data not shown).
In METABRIC, TNBCs also exhibited significantly
higher mRNA expression of FANCL (p < 0.0001), SYK
(p < 0.0001), ELF3 (p < 0.01), JAK2 (p < 0.0001), and
GSK3B (p < 0.0001) compared with non-TNBCs (Additional file 3: Figure S1a). There was no significant change
in CEP76. In TCGA, TNBCs exhibited significantly higher
mRNA expression of FANCL (p < 0.0001), SYK (p < 0.0001),
and CEP76 (p < 0.0001) compared with non-TNBCs
(Additional file 3: Figure S1b). No significant changes
in ELF, JAK2 and GSK3B were observed. Further,
compared with normal tissue, median mRNA expression of these eight genes was significantly elevated in
breast cancer tissue (Additional file 3: Figure S1c).
CCNE1 amplification is associated with poor overall
survival in the “Discovery-TNBC” cohort

In the “Pilot-TNBC” cohort, CCNE1 amplification was
not observed. Further analysis of an independent cohort
of “Discovery-TNBC” revealed CCNE1 amplification
(CN ≥ 6) in 6 of 55 (10.9%) patients (primary and metastatic tumors). The clinical characteristics and outcomes
of these patients with CCNE1-amplified TNBC are summarized in Table 2. Patients with CCNE1-amplified tumors
presented with advanced stage disease and had poor pathological responses to neoadjuvant chemotherapy. None of

these patients had BRCA1/2 mutations. There is a statistically significant association between CCNE1 amplification
and poor OS (p = 0.023) (Fig. 4a), but not RFS (p = 0.25)
(Fig. 4b).
Of the “Discovery-TNBC” cohort (n = 55), whole-transcriptome sequencing (RNAseq) was successful in 35
paired primary-metastatic specimens. Of those, 25 specimens exhibited an increase in CCNE1 mRNA expression
in metastatic samples compared to their primary counterparts. No association between CCNE1 mRNA over-expression and OS was observed in the “Discovery-TNBC” cohort
(p = 0.45) (Fig. 4c).
We further examined the association of CCNE1 gene
expression and CCNE1 gene amplification in both primary and metastatic tumors (Fig. 4d). In tumors with no
CCNE1 amplification (CN < 6), the mean and variance of
CCNE1 mRNA expression were comparable between
primary and metastatic tumors. However, the mean
CCNE1 expression in metastatic tumors was increased
compared to primary tumors (expression = 5.29 vs. 3.87,
SD = 0.49 vs. 2.02).
CCNE1 amplification was more frequently detected in
TNBCs (9%, 27/299 in METABRIC and 10%, 11/111 in
TCGA) compared to non-TNBCs (1.7%, 27/1605 in
METABRIC, p < 0.0001 and 3.5%, 33/962 in TCGA, p =
0.0055), but these distinctions did not translate into significant OS differences, likely due to limited sample sizes. In
TCGA, TPX2 amplification was more frequent in TNBCs
(8.1%, 9/111) compared to non-TNBCs (1.5%, 14/962) (p =
0.0004), but not in METABRIC. Interestingly, reflective of
our “Discovery-TNBC” cohort data, CCNE1 amplification
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Fig. 3 TNBCs exhibited higher mRNA expression of CCNE1 and TPX2 compared with non-TNBCs (Wilcoxon signed rank test) in (a) METABRIC:
TNBC (n = 299) and non-TNBC (n = 1605) (p < 0.0001 for both CCNE1 and TPX2) and in (b) TCGA: TNBC (n = 115) and non-TNBC (n = 976) (p < 0.0001 for
both CCNE1 and TPX2), y-axis is the log2 of TPM values by RSEM. In TNBCs, CCNE1 is significantly co-overexpressed with TPX2 in (c) METABRIC: TNBC
(n = 299, p < 0.001, r = 0.65) and in (d) TCGA: TNBC (n = 115, p < 0.001, r = 0.63)

Table 2 Clinical characteristics and outcomes of patients with CCNE1-amplified tumors in the “Discovery-TNBC” cohort
Patient ID

Age

Stage

(Neo)Adjuvant
chemotherapy

Response to neoadjuvant
chemotherapy

Adjuvant radiation

RFS (months)

OS (months)

1

50

2

50

I

Declined

N/A

No

58

N/A

III

TAC

ypT2N0Mx

No

11

23

3
4

46

III

AC Carbo/nab-paclitaxel

ypT3N1Mx

Yes

24

55

36

III

AC-T

ypT0N1Mx

Yes

13

18

5

35

III

Carbo/taxol

ypT3N2aMx

Yes

3

21

6

46

III

Carbo/taxol

ypT3N3aMx

Yes

13

43

7

50

II

Docetaxel, cisplatin

ypT1N1Mx

Yes

8

15

8

46

III

Carbo/taxol, AC

ypT2N2aMx

Yes

11

20

9

36

II

Carbo/nab-paclitaxel

ypT1cN0Mx

Yes

8

24

10

55

III

AC-T (adjuvant)

pT4N2aMx

No

46

60

11

46

II

Carbo/taxol (adjuvant)

pT2N1Mx

No

21

34

12

53

III

AC-T

ypT1N1aMx

No

9

16

13

48

II

TC

ypT1cN1Mx

Yes

3

38

AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide followed by paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/
cyclophosphamide, TC docetaxel /cyclophosphamide, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death)
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Fig. 4 CCNE1 amplification is associated with poor overall survival (n = 62, comprised of 55 patients from the “Discovery-TNBC” cohort and 7
patients from clinical report). (a) TNBCs with CCNE1 amplification (CN > 6) correlate with poor OS (p = 0.023); (b) No significant correlation was
observed between patients’ RFS and CCNE1 amplification (p = 0.25), “CCNE1 amp = 0” represents tumors without CCNE1 amplification (CN < 6),
“CCNE1 amp = 1” represents tumors with CCNE1 amplification (CN ≥ 6); (c) No significant correlation was observed between patients’ OS and
CCNE1 mRNA expression level (p = 0.45), “CCNE1 mRNA change = 0” represents tumors without CCNE1 mRNA overexpression (below median),
“CCNE1 mRNA change = 1” represents tumors with CCNE1 mRNA overexpression (above median); (d) Analysis of the association of CCNE1 gene
expression and CCNE1 copy number (CN) alteration in primary and metastatic TNBCs showed that mean and variance of CCNE1 mRNA expression
was comparable between primary and metastatic tumors. Mean CCNE1 gene expression in metastatic tumors was increased compared to primary
tumors (expression = 5.29 vs. 3.87, SD = 0.49 vs. 2.02)

in TNBC is mutually exclusive with BRCA1/2 mutations in
both METABRIC and TCGA breast cancer databases.

Discussion
Tumor genomic evolution is frequently observed due
to selection pressure imposed by chemotherapy. We

hypothesize that studying paired primary-metastatic
TNBCs at the genomic and transcriptomic levels may
lead to a better understanding of the underlying
mechanisms behind chemotherapy resistance. Herein,
we report mRNA expression profiling and targeted
DNA sequencing data from paired primary-metastatic
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TNBCs in a “Pilot-TNBC” cohort and an independent, expanded “Discovery-TNBC” cohort. Despite
largely concordant gene expression levels, 8 putative
cancer driver genes were significantly upregulated in
metastatic samples compared to their matched primary specimens. Furthermore, CCNE1 amplification
was associated with poor overall survival in the “Discovery-TNBC” cohort, highlighting CCNE1 amplification as a
possible mechanism of chemotherapy resistance.
TNBCs are extremely heterogeneous. In an effort to
better understand and categorize TNBCs, several molecular classifiers were developed (i.e. Lehmann/Pietenpol [3] and Burstein [4]). Although these classifiers have
improved our understanding of TNBC tumor biology
and helped distill scientific analyses into outputs that are
more easily interpretable, none have led to changes in
clinical practice. Herein, we identified so-called “molecular phenotype shifts” between select primary and metastatic samples from our “Pilot-TNBC” cohort, but a
universal shift in TNBC pheno-subtypes was not observed. The clinical application of these findings requires
further investigation.
Previous studies have reported variable findings upon
comparison of primary and metastatic tumors. Some revealed concordant expression patterns between primary
breast cancers and their matched synchronous lymph
nodes [16, 35–37]. Vecchi, et al. found that expression
of a specific gene set could differentiate between primary
tumors and synchronous metastases [38]. However, Weigelt, et al. studied seven cases of primary breast cancer and
asynchronous distant metastases and showed that a
70-gene prognostic signature was generally maintained in
the switch from primary to metastasis across most of the
pairs [39]. Several studies used targeted NGS to address
genomic concordance between primary and metastases.
Meric-Bernstam and colleagues reported that 86.6% of the
somatic mutations and 62.3% of the copy number variations were concordant between primary tumors and recurrences [7]. These studies suggest that it may be necessary
to study circulating tumor DNA (ctDNA), which is thought
to be more representative of the mutational spectrum of
the entirety of a patient’s metastatic disease rather than a
biopsy of a single metastatic lesion [40]. Furthermore, noncoding RNAs and epigenetic modifications could also play
an important role in the metastatic process [16, 41, 42].
Cyclin E and its associated CDK2 are essential for cellular progression through the G1 phase of the cell cycle
and initiation of DNA replication. CCNE1 amplification
induces chromosome instability through persistent DNA
replication and centrosome duplication [43–45]. CCNE1,
along with its catalytic subunit CDK2, plays a critical
role in cell cycle regulation to assure precise control of
DNA replication, chromosome segregation and the G1
to S-phase transition [11, 12]. CCNE1 amplification is
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mutually exclusive with BRCA1/2 mutations and correlates with cyclin E1 protein expression in ovarian cancer
[46–48]. CCNE1 amplification occurs in approximately
20% of high-grade serous ovarian carcinomas (HGSCs)
[13, 14] and is associated with primary treatment resistance and poor outcome in these tumors [49]. Cyclin
E1-specific pharmacological inhibitors are not yet available, although indirect CCNE1 targeting trials are ongoing. However, small molecule inhibitors do exist for
CCNE1’s counterpart in the cell cycle, CDK2. The pan
CDK inhibitor, dinaciclib (SCH-727965), inhibits CDKs
2/5/1/9 and is being tested in clinical trials for hematological and solid malignancies (NCT00798213 and
NCT00937937) [50, 51]. In addition, a WEE1 inhibitor
AZD1755 is being tested in solid tumors with CCNE1
amplification (NCT03253679). In a study of HGSC, expression of TPX2, a centromeric protein required for mitotic spindle function, was highly associated with CCNE1
amplification [47]. In our study, CCNE1 and TPX2 were
co-overexpressed in metastatic TNBCs compared to
paired primaries. This finding is similar to previous results
in ovarian cancer, where co-overexpression of CCNE1 and
TPX2 were found to be related to clonal resistance to
chemotherapy [47]. Mutual exclusivity of BRCA1/2 mutation/deletion and CCNE1 amplification has been shown
previously in ovarian cancers [47]. Despite limited sample
size, our finding of mutual exclusivity of CCNE1 and
BRCA1/2 genes is worth further investigation and may
help clinicians select patients for personalized treatment.
High cyclin E1 expression has been considered in
other studies as a biomarker of poor clinical outcome
in breast cancer [15, 52]. In a study of patients with
HER2+ disease, CCNE1 amplification/overexpression
resulted in worse survival and CDK2 inhibition could
overcome trastuzumab resistance in xenograft models
[15]. Hunt, et al. demonstrated that overexpression
of cytoplasmic low molecular weight cyclin E (LMW-E)
is associated with poor survival in patients with breast
cancer [53]. Because it lacks a nuclear localization domain, LMW-E accumulates in the cytoplasm, where it
binds to CDK2 and retains kinase activity [54]. Our
study provides further evidence of the association of
CCNE1 amplification and poor OS in patients with recurrent TNBCs. CCNE1 mRNA was significantly upregulated in metastatic compared to paired primary
TNBCs. Although no survival differences were observed, this may be reflective of the limited sample size.
This study features a combination of well-annotated clinicopathologic and genomic data, which allowed us to directly identify clinically relevant genomic information.
However, our study is limited by sample size, lack of unified
treatment variables, and retrospective nature. We did not
study noncoding RNAs nor epigenetic changes within the
tumors. Finally, although patient-matched, singular biopsies
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do not represent a complete picture of metastatic disease.
Overall, our study is hypothesis-generating and these results will benefit from verification with a larger cohort of
patients and more comprehensive technologies and tumor
biology assessments such as ctDNA analyses.

Conclusions
In this study, comparison of paired primary and metastatic TNBCs demonstrates heterogeneity of molecular
mechanisms of gene expression underlying TNBC recurrence. Amplification of CCNE1 is associated with poor
OS in patients with metastatic TNBC. CCNE1 amplification may serve as a target for therapeutic intervention in
chemotherapy-resistant TNBCs.
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